<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03863171</url>
  </required_header>
  <id_info>
    <org_study_id>2018-P2-185-02</org_study_id>
    <nct_id>NCT03863171</nct_id>
  </id_info>
  <brief_title>Early Diagnosis for Ocular Ischemia Syndrome Using Arterial Spin Labeling Magnetic Resonance Imaging Technique</brief_title>
  <official_title>Early Diagnosis for Ocular Ischemia Syndrome Using Arterial Spin Labeling Magnetic Resonance Imaging Technique: a Prospective Multicenter Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To evaluate ocular blood perfusion status and the possibility of craniocerebral vascular&#xD;
           lesions of patients with ocular ischemia syndrome (OIS) using arterial spin labeling&#xD;
           (ASL) magnetic resonance imaging technique.&#xD;
&#xD;
        2. To evaluate the specificity, sensitivity and accuracy of arterial spin labeling (ASL)&#xD;
           magnetic resonance imaging technique in OIS diagnosis, compared with the traditional&#xD;
           routine examination method.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Flow (BF)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Blood Flow (BF)ï¼ša parameter measured by arterial spin labeling perfusion MRI to qualify the perfusion in tissue-specific units (ml blood/gram tissue/time)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Ocular Ischemia Syndrome</condition>
  <arm_group>
    <arm_group_label>Ocular ischemia syndrome</arm_group_label>
    <description>Patients with ocular ischemia syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients with age-related macular degeneration</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Arterial spin labeling (ASL) magnetic resonance imaging</intervention_name>
    <description>Arterial spin labeling (ASL) magnetic resonance imaging test</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Ocular ischemia syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fundus fluorescein angiography</intervention_name>
    <description>Fundus fluorescein angiography test</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Ocular ischemia syndrome</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ocular ischemia syndrome&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ocular ischemia syndrome group: Patients diagnosed with ocular ischemia syndrome;&#xD;
&#xD;
          -  Age-related macular degeneration group (Control group): Patients diagnosed with&#xD;
             age-related macular degeneration;&#xD;
&#xD;
          -  Age: 50-80 years;&#xD;
&#xD;
          -  Sex: all;&#xD;
&#xD;
          -  Patients signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fundus fluorescein angiography (FFA) clear images cannot be obtained due to refractive&#xD;
             media problems(such as corneal leukoplakia, severe cataract, vitreous hemorrhage,&#xD;
             etc.) ;&#xD;
&#xD;
          -  Patients with contraindications for FFA;&#xD;
&#xD;
          -  Patients was unable to perform magnetic resonance rmaging (MRI) test;&#xD;
&#xD;
          -  Patients with history of bleeding and cerebral infarction;&#xD;
&#xD;
          -  Patients with a history of surgery within 3 months;&#xD;
&#xD;
          -  Patients who had participated in other clinical trials within 3 months;&#xD;
&#xD;
          -  Patients who disagree and refuse to participate in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Yanling Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanling Wang, MD</last_name>
    <phone>+86-13701277114</phone>
    <email>wangyanling999@vip.sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanling Wang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Yue Li</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

